Background/Aims: Hepatitis B virus (HBV) infection is a major cause of cirrhosis and hepatocellular carcinoma. Therefore, we aimed to obtain further information on HBV pathogenesis, and to search for novel putative molecules for anti-HBV therapy. Methods: We utilized Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) to identify the secretory proteins that are differentially expressed in the HBV DNA-transfected HepG2.2.15 cell line and its parental HepG2 cell line. Immunohistochemistry (IHC) was employed to assess the clinical relevance of the observations. Small interfering (si)RNA-based silencing transfection methods were carried out to study the function of ENPP2. Results: Totally, 133 unique proteins were identified as differentially expressed in HepG2.2.15 cell line compared with HepG2 cell line. Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 precursor (ENPP2) is one of the most significantly up-regulated secretory proteins associated with HBV replication. This differential expression of ENPP2 was further validated by real-time quantitative RT-PCR, Western Blot and immunohistochemical analysis. To study the function of ENPP2, we knockdown ENPP2 expression in HepG2.2.15 cell line by RNA interference. ENPP2 silencing increased HBV replication approximately 2.3-fold by enhancing, via the type I IFN signaling pathway, HBV cccDNA (covalently closed circular DNA) translation into viral RNA. Moreover, attenuation of ENPP2 expression inhibited both the invasion and migration ability of hepatoma cells in vitro via interacting with the molecules in the tumor microenvironment. Conclusion: Our study demonstrates that ENPP2 may be a novel anti-HBV target and indicate that suppression of its expression may inhibit the invasion and migration ability of hepatoma cells.
Introduction
It is estimated that, globally, two billion individuals are infected by the hepatitis B virus (HBV) [1] . Among them, over 350 million have developed liver injury [1] . Epidemiological studies have demonstrated that chronic HBV disease can progress to liver cirrhosis, exposing the patient to risks of liver failure and hepatocellular carcinoma (HCC). Annually, more than one million people die from HBV-related liver diseases, and thirty to fifty percent of those deaths are due to HCC [2] . Therefore, it is of critical importance to refine our understanding regarding the host-based mechanisms related to HBV replication and pathogenesis [1] .
The lack of appropriate cell models supporting HBV replication has hindered the progress of pathogenetic studies on HBV infections. However, comparative proteomic analysis through large-scale investigations of protein profiles represents a promising approach in different kinds of pathogenic situations. This method has been applied to the HepAD38 and HepG2.2.15 cell lines, both of which originated in an HCC cell line named HepG2 and were integrated with a length of HBV genome more than one unit [3] . These investigations gave an insight into the characterization and identification of unique proteome profiles linked to HBV infection in immortalized hepatocytes [4, 5] . Although valuable knowledge on HBV activities during infection were provided, the utilized expression techniques resorted to "bulk" homogenates of cell lines, and did not provide preferential enrichment for the secreted proteins [6] , which are expected to involve the most promising extra-cellular regulatory factors for HBV replication. In addition, two-dimensional gel electrophoresis (2-DE) techniques have some drawbacks, such as excessive time, low sensitivity, inter-gel variation, and high labor costs [7] . To overcome these technical limitations, we have focused on the secretome of HBV replication using newly emerging proteomic approaches. In the last few years, increasing interest has been drawn in developing isotope-based quantitative proteomics for researching complex or dynamic biological processes, varying from biomarker identification to monitoring of condition-specific post-translational modifications. These rising techniques include stable isotope labeling by amino acids in cell culture (SILAC), isobaric tags for relative and absolute quantification (iTRAQ), and the isotope-coded affinity tags (ICAT) [8] [9] [10] .
In this investigation, we compared differential expression of secreted proteins between HepG2.2.15 and HepG2 cells by employing the iTRAQ method, which allows for the labeling and analysis of 8 samples in a single experiment. The iTRAQ-coupled 2D LC−MS/MS analysis revealed that 133 secreted proteins were differentially expressed in HBV infection. Autotaxin (ENPP2), which was one of the most over-expressed proteins, was selected for further functional studies.
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© 2018 The Author(s). Published by S. Karger AG, Basel www.karger.com/cpb She et al.: ENPP2 is an Endocellular Anti-Hepatitis B Virus Factor identification was based on a selection threshold of ProtScore > 1.3, and for quantitation, at least two unique peptides with 95%, 5% FDR, and FDR adjusted P-values < 0.05 using Bonferroni correction [15] were required. Proteins were relatively quantified by using the ratio of the areas under the peaks of 117−119, and 121 Da, which were the masses of the iTRAQ tags that were applied to label the samples.
RT-PCR analysis
To verify the reliability of the iTRAQ results, RT-PCR analysis was performed to confirm the expression level of several genes according to their most significant ratios or relevance to virus. The genes evaluated were SPINK1 (ratio 50.12:1), SPOCK2 (ratio 16.29:1), GDF15 (ratio 8.24:1), C4BPA (ratio 6.85:1), TIMP1 (ratio 6.14:1), ORM1 (ratio 4.97:1), ENPP2 (ratio 4.97:1), PCBD1 (ratio 23.12:1), LARS (ratio 17.38:1), MARCKS (ratio 12.70:1), SEMA3A (ratio 12.13:1), FGL1 (ratio 0.01:1), SERPINC1 (ratio 0.03:1), CLU (ratio 0.08:1), AFP (ratio 0.13:1), and FN1 (ratio 0.16:1). Trizol reagent (Gibco, Grand Island, NY, USA) was used to extract total RNA according to the manufacturer's instructions. The cDNA was produced by reverse-transcription of the total RNA by employing the Promega Reverse Transcription System A3500. An ABI 7900HT System (Applied Biosystems, Foster City, CA) was used for quantitative RT-PCR using gene-specific primers for SPINK1 (Hs00162154_m1), SPOCK2 (Hs00360339_m1), GDF15 (Hs00171132_m1), C4BPA (Hs00426339_m1), TIMP1 (Hs00171558_m1), ORM1 (Hs01590790_g1), ENPP2 (Hs00905117_m1), PCBD1 (Hs00165396_m1), LARS (Hs00219931_m1), MARCKS (Hs00158993_m1), SEMA3A (Hs00173810_m1), FGL1 (Hs00189514_ m1), SERPINC1 (Hs00166654_ m1), CLU (Hs00156548_m1), AFP (Hs00173490_m1), FN1 (Hs00365052_m1), and GAPDH (Hs02758991_g1 
Western blotting analysis
Immunoblotting was performed as previously reported [13] . Tissues/cells were treated with lysis buffer containing Tris-HCl, IGEPAL, (1:20) , and subsequently washed with Wash Buffer and incubated with the ENPP-2 Conjugate. After the Substrate Solution and Stop Solution were added, the concentration of ENPP2 was obtained with four-parameter logistic curves, which were fitted with the standard value and multiplied by the dilution factor. All measurements were carried out in duplicate.
Tissue microarrays and immunohistochemistry
To further analyze the expression of ENPP2, ORM1 and SPOCK2 proteins in HCC, immunohistochemistry (IHC) was performed. Tissue microarrays (LV801a; Biomax, Inc, Rockville, MD, USA) contained 40 hepatocellular carcinoma cases, plus 40 matched or unmatched adjacent normal tissues, with a single core per case. The specifications of the samples are shown in Table 2 . Immunohistochemistry was performed as previously reported [13] . Paraffin-embedded liver sections were deparaffinized, rehydrated, and then processed by heat-induced antigen retrieval in 0.01 M citrate for 5 min. 3% H 2 O 2 was used (5 min) to quench endogenous peroxidase activity. After blocking with bovine serum albumin, the sections were incubated overnight with primary antibodies to ORM1 (1:100), SPOCK2 (1:100) and ENPP2 (1:100). The Envision/ horseradish peroxidase system (Dako-Cytomation, Glostrup, Denmark) was used for protein detection, and Gill's hematoxylin was used for counterstaining slides. The slides were dehydrated and mounted for evaluation under a light microscope.
Semi-quantification of protein expression was defined by a scoring criteria as previously described [17] . The percentage of positive cells (0−100%) and the positive staining intensity (scale 0−3) were recorded, and were multiplied to yield a score of 0 to 300. In order to maintain consistency, the same qualified pathologist gave interpretations for all IHC data. 
ENPP2

pcDNA3.1-ENPP2 transfection and supernatant HBV detection
To assess whether ENPP2 overexpression could generate an effect opposite to that of siRNA silencing, HepG2.2.15 cells were transfected with pcDNA3.1-ENPP2, an ENPP2 expressing plasmid. To exclude the effect of cell division or proliferation on hepatitis B virus replication, the HepG2.2.15 cells were treated with dimethyl sulfoxide (DMSO). After transfection for 48 hours, the culture media were harvested. Supernatant HBV DNA copies were detected as described above.
Trans-well assay
Taking into account the role of ENPP2 in tumor cell motility [19] [20] [21] , HepG2.2.15 and HepAD38 cell lines were pretreated with ENPP2-siRNA as described above and subjected to trans-well assays. After cells were approximately 80% confluent in 100 mm plastic dishes, their viability was determined by trypan blue dye exclusion to be over 95%. The transwell assay was performed to assess the migration and invasion ability of cells by using a CytoSelect™ 24-Well Cell Migration and Invasion Assay Kit (Cell Biolabs, San Diego, CA, USA) according to the manufacturer's instructions. After having assessed the cell viability, approximately 10 5 siRNA-transfected cells were seeded onto the upper well and, the number of cells that pass through the membrane without or with matrigel was determined by CyQuant GR fluorescent dye (560 nm) at 12 hours or 24 hours post-seeded.
Statistical analysis SPSS software v13.0 (Chicago, IL) was used for statistical analysis. Quantitative variables are presented as the mean with standard deviation (SD) or median (range), and comparisons between groups were analyzed by a Student's t-test or a Mann-Whitney U-test. Qualitative variables are presented as counts and percentages, and were compared by the χ2 test. A P-value less than 0.05 was considered statistically significant, and all tests of significance were two-tailed.
Results
iTRAQ identification and quantification of aberrantly expressed proteins
To investigate the mechanisms involved in HBV replication, the quantitative proteomics analysis using iTRAQ tags was performed with HepG2 and HepG2.2.15 conditioned media. In order to increase the confidence of data and/or the coverage of protein identification, duplicate iTRAQ labeling was performed as follows: HepG2 cells were labeled with 117-tags and 119-tags; HepG2.2.15 cells were labeled with 118-tags and 121-tags. Fig. 1 shows a schematic view of the iTRAQ methodology.
As described previously, two or more peptides were used for quantification and protein identification. For ProteinPilot-based database searching and identification, the threshold [unused protscore (conf)] was set to achieve 95% confidence at 5% FDR. The protein identification threshold, a ProtScore value of more than 1.3, was used to attain a confidence of 95%. For the subsequent relative quantification analysis, despite statistical analysis being part of the ProteinPilot software, an additional > 1.3 (1×1.3) or < 0.77 (1/1.3)-fold cutoff was applied to all iTRAQ ratios to minimize false positives when determining proteins as over-or under-expressed. This cutoff value was adopted since overall technical variation of data from the duplicate experiments was estimated below 30%, and, in other investigations using the iTRAQ approach, this value is widely employed [22] [23] [24] [25] . Thus, proteins with iTRAQ ratios below 0.77 were considered to be under-expressed, while those > 1.3 were deemed to be overexpressed [13] . According to this strategy, 796 unique proteins were successfully identified by using two or more peptides (Data not shown) and 133 proteins exhibited differential expression between virus-producing HepG2.2.15 cells and virus-free HepG2 parent cells (Table 3 ). Due to limitations with this approach, we used immunoblotting and IHC to further verify the main findings.
Validation of abnormally expressed proteins
Immunoblotting and real-time quantitative polymerase chain reaction (RT-PCR) were conducted to confirm protein expression levels based on iTRAQ analysis. Fig. 2A displays the mRNA abundance of SPINK1, SPOCK2, GDF15, C4BPA, TIMP1, ORM1, ENPP2, PCBD1, LARS, MARCKS, SEMA3A, FGL1, SERPINC1, CLU, AFP and FN1 with their normalization to GADPH. The abundance of SPINK1, SPOCK2, GDF15, C4BPA, TIMP1, ORM1, ENPP2, PCBD1, LARS, MARCKS and SEMA3A were enhanced in cell line HepG2.2.15. Conversely, the abundance of the remaining mRNAs was reduced compared to the HepG2 cell line. These results matched well with those achieved by the iTRAQ analysis. As assessed by western blotting (Fig. 2B) , the HepG2.2.15 cell line presented increased levels of ENPP2, ORM1 and SPOCK2, contrasting with decreased levels of AFP and FGL1, as compared to the HepG2 cell line.
To date, neither ENPP2, ORM1, nor SPOCK2 proteins have been previously reported to be abnormally expressed in HBV patients; therefore, we explored the different expression levels of these proteins in 14 normal liver tissues, 20 HBV-infected liver biopsy specimens and 20 HCC tissues. Fig. 3A shows remarkably high levels of ENPP2, ORM1, and SPOCK2 proteins in HBV-infected liver biopsy samples. Higher levels of ENPP2, ORM1 and SPOCK2 protein expression were also observed in HCC specimens versus normal specimens or HBV-infected ones. Fig. 3B shows the expression level of ENPP2 in all tissue specimens in a waterfall plot.
Since high levels of ENPP2, ORM1 and SPOCK2 were observed in HCC, these proteins were further assessed in tissue microarrays containing tumor and non-tumor tissues by IHC. As shown in Fig. 4 , a significant number of HCC tissues expressed ENPP2, ORM1 and SPOCK2 at higher levels than those detected in the non-tumor tissues. Specifically, 38/40 (95%) of HCC samples expressed ENPP2, as opposed to no expression in non-tumor samples. When compared with non-tumor tissues, ORM1 and SPOCK2 in HCC tissues showed a similar trend.
To establish the clinical relevance of our finding, plasma levels of ENPP2 were determined in 98 cases, including 57 HCC, 23 CHB and 18 normal controls. As assessed by an enzymelinked immunosorbent assay (ELISA), there was a significantly higher concentration of ENPP2 in the CHB group (290.63 ng/ml) than in the normal control (233.33 ng/ml, P < 0.05), but the highest concentration was found in the HCC group (385.48 ng/ml, P<0.01) (Fig. 5) . These results are consistent with those achieved via proteomic analysis. 
Fig. 3. Western blot analysis. (A)
A representative Western Blot for ENPP2, ORM1, and SPOCK2 expression in normal liver tissues (n=14), HBV-infected liver biopsy specimens (n=20) and HCC tissues (n=20). Three separate gels were rearranged, one for each group. The five lanes in left, middle and right represented normal liver tissues samples, HBV-infected liver biopsy specimens and hepatitis B virus-associated hepatocellular carcinoma tissues samples. All samples were derived and processed in parallel at the same time, and normalized to the internal control. A remarkably high level of ENPP2, ORM1, and SPOCK2 protein expression was detected in liver biopsy specimens of HBV-infected patients, compared to normal individuals. The experiments were performed in triplicate. (B) The expression level of ENPP2 in all tissue specimens was presented in a waterfall plot. The band intensity of each sample was normalized to the internal control, and the minimal value in normal liver tissues was served as 1 fold change. The upper and lower limits of the boxes and the lines inside the boxes indicate the 75th and 25th percentiles and the median, respectively. Upper and lower horizontal bars denote the maximal and minimal values. The plotted error bars reflect technical variations. *P＜0.05. Bars indicate SD. 
ENPP2 as a potential target to suppress HBV replication
Since literature data and bioinformatic analysis suggest the functional involvement of ENPP2 in Epstein-Barr viral infection [26] , and we found it to be up-regulated both in vitro and in vivo, we hypothesized that there was a link between HBV replication and the ENPP2 protein. Accordingly, one control siRNA and two ENPP2-specific siRNA sequences were used to transfect the HepG2.2.15 virus-producing cell line. Each of the ENPP2-specific sequences effectively silenced ENPP2 expression. As expected, the control siRNA did not silence ENPP2 expression (Fig. 6A ). RT-PCR was then utilized to quantitate the HBV-DNA levels of two types of ENPP2 knocked-down HepG2.2.15 cells and control. As shown in Fig. 6B , HBV-DNA production, as well as excretion of HBsAg and HBeAg, was increased in the supernatant of ENPP2-siRNA treated cells. The HBV-DNA titer increased nearly 2.3-fold as compared to control group. In addition, we determined the transcriptional alteration of type . Plasma levels of ENPP2 were determined in 98 cases, including HCC cases(n=57), CHB cases(n=23) and normal controls(n=18). There was a significantly higher concentration of ENPP2 in the CHB group (290.63 ng/ml) than in the normal control (233.33 ng/ml, *P<0.05), but the highest concentration was observed in HCC group (385.48 ng/ml, **P<0.01). Bars indicate SD. 
Figure 7
EIF-2α, OAS1, OAS3, PKR, and ISG15, were observed in response to ENPP2 silencing. Nevertheless, minimal transcriptional changes were found in three further effectors (OAS2, OASL, and MX1). As shown in Fig. 6D , compared to the control cell, the expression of pS473-Akt and pS727-STAT1 was decreased in ENPP2-knockdown HepG2.2.15 cells.
To confirm the role of ENPP2 in regulating viral replication, a rescue experiment was performed. The ectogenic ENPP2 rescued ~39% HBV replication induced by ENPP2-siRNA transfection, and did not show statistically significant differences compared to the control group (Fig. 7A) . On the other hand, ENPP2 overexpression generated the opposite effect to siRNA silencing, with a nearly 2-fold decrease of HBV-DNA titer in the pcDNA3.1-ENPP2 transfection group, but not in the pcDNA3.1 group (Fig. 7B, C) .
ENPP2 is involved in HCC cell invasion and migration
ENPP2 has been proven to stimulate the migration and invasion of melanoma cells [27] and mammary carcinoma cells [28] . Wu et al. demonstrated that secreted ENPP2 with enzymatic activity could stimulate cell invasion of Hep3B, a cell line derived from a patient with hepatitis [20] . To confirm the effect of ENPP2 on HCC invasion and migration, we inhibited ENPP2 expression in HepG2.2.15 cells and HepAD38 cells using siRNA technology. Effective silencing of ENPP2 expression was verified for HCC cells transfected with the ENPP2-specific siRNA, but not with the control siRNA. Consistent with previous results, our invasion and migration assay revealed that ENPP2 down-regulation decreased the mobility of HepG2.2.15 cells and HepAD38 cells by 35.7-42.2% and 38.9-47.8%, and decreased the invasiveness by 27.5-33.4% and 31.2-37.1%, respectively, compared to controls (P < 0.05) (Fig. 8B, D) .
Discussion
Individuals with chronic HBV infection are at risk to develop chronic liver diseases, which can progress to cirrhosis and HCC. Understanding the pathogenesis and molecular mechanisms of HBV replication is a critical first step to improve the accuracy of patient screening methods and efficacy of treatment regimens. Moreover, such data will likely identify novel factors and pathways that may represent targets for new therapeutic drugs and vaccines. In our investigation, the iTRAQ proteomic method was employed to identify secreted proteins in HepG2.2.15 and HepG2 cell lines. As a result, 133 proteins were identified as being associated with HBV replication, and 16 of these were verified by RT-PCR and immunoblotting technique. Finally, ENPP2 was shown to interfere with HBV replication. These findings not only yield evidence that the iTRAQ labeling method is a powerful and reliable method for quantifying proteins on a large scale, but also provided insights into the host proteins and related functional mechanisms that may underlie virus survival and pathogenesis. Several key proteins identified in our work will be discussed.
The intracellular and extracellular expression levels of ENPP2, also named autotaxin (ATX) [29] , were found to be significantly increased in HepG2.2.15 cell lines and in patients with HBV infection. Thus, ENPP2 expression seemed to be responsive to HBV infection and participates in its etiopathogenesis. ENPP2 may be a link between hepatitis C and hepatocellular cancer, and its expression was enhanced in human hepatitis associated HCC [30] . However, whether ENPP2 can affect replication of hepatitis B virus remained unknown. Recognized as an enzyme secreted by the liver, ENPP2 exerts lysophospholipase D (lysoPLD) activity for generating lysophosphatidic acid (LPA) from lysophosphatidylcholine (LPC) [31] . Moreover, ENPP2 seems to be the predominant enzyme-generating LPA in plasma and serum [32, 33] . It is reported that PI3K/Akt signaling pathway could be activated at the beginning of various cytopathic viruses infections, including Coxsackie B virus, rubella virus, and respiratory syncytial virus [34] . However, the interplay between the PI3K/Akt signaling pathway and non-cytopathic viruses, such as HCV or HBV, has been discussed only recently. Mannova et al. showed that the PI3K-Akt pathway could be activated after HCV infection to limit virus replication and promote cell survival [35] . Guo et al. reported that constitutively active Akt1 profoundly suppresses the transcription of HBV pre-genomic RNA (pgRNA) and 2.4-kb mRNA, which were transcribed from HBV covalently closed circular DNA (cccDNA) and necessary for viral protein production and viral replication [36] . Moreover, when HepG2.2.15 cells were exposed to inhibitors of PI3K, Akt, and mTOR, an increase in both transcription of 2.4-kb and 3.5-kb viral RNA and replication of HBV DNA was observed [34] . Consequently, they proposed that Akt activation during the oncogenic transformation of hepatocytes, along with other cellular changes, may be responsible for the elimination of HBV replication from tumor and even precancerous cells [34] . Similarly, Ji et al [37] . showed that PI3K-Akt signaling is associated with up-regulation of the IFN response. Higher PI3K-Akt activity might impede viral propagation due to activation of cellular defenses [37] . Belloni's group further confirmed that IFN could inhibit HBV replication by decreasing the transcription of pgRNA from the HBV cccDNA minichromosome [38] . Since LPA can act on distinct G proteincoupled receptors, it plays an important role in activating multiple signaling cascades [39] , including, but not exclusively, the PI3K/Akt signaling pathway [40] . When inhibitors of LPA were added, phosphorylation of the PI3K/Akt pathway was reduced [40] , affecting in turn the phosphorylation of STAT1 [41] and the activation of gene expression. Additionally, IFNactivated JAK-STAT pathways were completed by activating the PI3K/Akt pathway [42] through allowing translation of IFN-stimulated genes, such as ISG15 [42] , and IFN β1 [43] . It was not unexpected that pS473-Akt and pS727-STAT1 expression was markedly decreased in ENPP2-knockdown HepG2.2.15 cells compared to the control group. Meanwhile, an approximate 2.3-fold increase in HBV production, together with an enhanced production of both HBeAg and HBsAg in culture medium, was observed. Additionally, mRNA levels of five downstream IFN-stimulated genes and type I IFN were significantly down-regulated in ENPP2-depleted HepG2.2.15 cells. Considering that decreased STAT1 phosphorylation has been reported to attenuate type I IFN-induced antiviral response [41] [42] [43] , our findings suggest that silencing of ENPP2 may decrease IFN mRNA through the PI3K/Akt pathway, and ultimately enhance HBV cccDNA translating into viral RNAs necessary for viral replication.
The biological role of ENPP2 was initially established as a motility factor [44] , and subsequently as a phospholipase D with catalytic capacity [32] . As one of the forty most upregulated genes in invasive cancer cells [45] , ENPP2 is widely implicated in tumor progression, invasion, and metastasis [46, 47] . Investigators have proved the oncogenic and pro-metastatic properties of ENPP2 in breast tumor cell lines and in MMTV-ENPP2 transgenic [28, 47] . In the context of hepatoma, ectopic expression of ENPP2 has been identified in HCC tissues [48] . In agreement with previous observations, forced expression of ENPP2 was observed in our clinical hepatoma samples, compared with HBV-infected liver biopsy specimens and normal liver specimens. Furthermore, down-regulation of ENPP2 expression, mediated by siRNA, dramatically decreased both migration potential and invasive ability of HepG2.2.15 and HepAD38 cell lines, which is consistent with the previous data by Wu et al. However, the involved mechanism was not fully understood. Wu's group deemed that ENPP2 was selectively promoted by the key inflammatory component TNF-α/NF-κB axis [20] , which indicated that ENPP2 might play a role in the connection between inflammation and tumorigenesis in the complex liver microenvironment. Furthermore, as a consequence of increased ENPP2 in HCC, LPA can contribute to HCC cell invasion and migration, while this promotion of LPA could be abolished by silencing of MMP-9 expression with MMP-9-targeted siRNA and blocking of MMP-9 activity with a MMP-9 neutralizing antibody [19] . Accumulated data support the critical role of MMP-9 in the formation of the metastatic niche [49] . Therefore, the aberrant expression of ENPP2 along with consequently abnormal production of LPA in the liver microenvironment may promote progression of liver tumors. Considering ENPP2 as a promising therapeutic target for the management of cancer, Gupte et al. noted that Analogues 22 and 30 b, the two most potent ATX inhibitors, inhibited the invasion of MM1 hepatoma cells across murine mesothelial and human vascular endothelial monolayers in vitro in a dose-dependent manner [50] . However, more suitable derivatives with further modifications will need to be explored in the future. Taken together, a more sophisticated assay is still needed to confirm the effect of ENPP2 on the biologic behavior of liver cancer cells. New research will dissect more precisely the mechanism of ENPP2 participation in HCC progression and the role of ENPP2 as a therapeutic target for the management of liver cancer. Among the proteins identified in our mass spectrometry data, the pancreatic secretory trypsin inhibitor (SPINK1) protein was found to be up-regulated prominently in the conditioned medium of HepG2.2.15 virus-producing cells. Lamontagne et al. found that SPINK1 could inhibit HBV and HCV replication by causing cell apoptosis in a serine protease-dependent manner [51] . Metalloproteinase inhibitor 1(TIMP1) and Alpha-1-acid glycoprotein 1 precursor (ORM1), were also strongly changed in HepG2.2.15 cell line. Previous study suggested that TIMP1 was correlated with liver fibrosis and ORM1 was a potential effect on the immune system during the acute-phase reaction [52] . Finally, some other proteins, including S100-A11 and immunoglobulin superfamily member 1 isoform 3, were found to be differentially expressed between HepG2.2.15 and HepG2 cell lines. Previously, these have not been linked with hepatitis B virus replication. Considering the functions of the identified differential proteins, it is reasonable to predict that these proteins were associated with the host-viral interaction.
Here, we have provided the first proteome-wide comparative profiles of the HepG2.2.15 and HepG2 secreted proteins. The resulting datasets of HBV-associated proteins represent a valuable resource for translational and basic research. In addition, the present study ascribes a new role for ENPP2, beyond the maintenance of host cellular functions, and broadens the spectrum of known viruses capable of interacting with and being affected by ENPP2. Our findings pave the road for considering ENPP2 as a novel therapeutic target in the field of HBV-related diseases.
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